Skip to main content

Advertisement

Log in

Neoadjuvant concurrent chemoradiotherapy with capecitabine and oxaliplatin in patients with locally advanced esophegeal cancer

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Evaluation of the feasibility and efficacy of neoadjuvant concurrent chemoradiotherapy (CRT) with capecitabine and oxaliplatin in patients with locally advanced esophageal cancer. Forty-two patients were eligible for the study. The chemotherapy during CRT consisted of two cycles of intravenous oxaliplatin of 120 mg/m2 on day 1 and oral capecitabine 825 mg/m2 twice daily on days 1–14 at 3-week intervals. The radiotherapy (1.8 Gy/fraction/day to a total dose of 45 Gy) was delivered to the primary tumor site and regional lymph node. All patients completed the planned treatment. Overall clinical response rate was 54.8% with complete response in 16.7% while pathological response rate was 38%. Anemia was the commonest hematologic toxicity (52.3%) with grade 3 in 4.7%, and esophagitis was the commonest non-hematologic toxicity 59.5% with grade 3 and 4 in 9.5%. No treatment-related death was observed. After a median follow-up duration of 19 months, the 2-year survival rate was 42%, median survival time was 20 months (95%CI: 13.802-26.198), while 2-year progression-free survival (PFS) rate was 32.5% with median PFS time of 15 months (95%CI: 10.042-19.958). Neoadjuvant concurrent CRT with capecitabine and oxaliplatin was found to be well tolerated and effective in patients with locally advanced esophegeal cancer; however, these results should be further evaluated in a phase III study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Lerut T, Coosemans W, Decker G, De Leyn P, Nafteux P, Van Raemdonck D. Cancer of the esophagus and gastroesophegeal junction: potentially curative therapies. Surg Oncol. 2001;10:113–22.

    Article  PubMed  CAS  Google Scholar 

  2. Falk J, Carstens H, Lundell L, Albertsson M. Incidence of carcinoma of the oesophegus and gastric Cardia-Changes over time and geographical differences. Acta Oncol. 2007;46:1070–4.

    Article  PubMed  Google Scholar 

  3. Siewert JR, Stein HJ, Feith M, Bruecher BL, Bartels H, Fink U. Histologic tumor type is an independent prognostic parameter in oesophegeal cancer: lessons from more than 1, 000 consecutive resections at a single center in the Western world. Ann Surg. 2001;234(3):360–7. discussion 368–9.

    Article  PubMed  CAS  Google Scholar 

  4. Piessen G, Mariette C, Triboulet JP. Cervical and upper third thoracic oesophegeal carcinoma: a single pathological entity? Ann Chir. 2005;130(2):86–91.

    Article  PubMed  CAS  Google Scholar 

  5. Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy and surgery compared with surgery alone for oesophegeal cancer. CALGB 9781. J Clin Oncol. 2008;26(7):1086–92.

    Article  PubMed  CAS  Google Scholar 

  6. Swisher SG, Hofstetter W, Wu TT, Correa AM, Ajani JA, Komaki RR, et al. Proposed revision of the oesophegeal cancer staging system to accommodate pathologic response (PP) following pre-operative chemoradiation. Ann Surg. 2005;241:810–20.

    Article  PubMed  Google Scholar 

  7. Brücher BL, Becker K, Lordick F, Fink U, Sarbia M, Stein H, et al. The clinical impact of histopathologic response assessment by residual tumor cell quantification in oesophegeal squamous cell carcinoma. Cancer. 2006;106:2119–27.

    Article  PubMed  Google Scholar 

  8. Byfield JE. Combined modality infusional chemotherapy with radiation. In: Lokich JJ, editor. Cancer Chemotherapy by Infusion. 2nd ed. Chigaco, IL: Percepta Press; 1990. p. 521–51.

    Google Scholar 

  9. AL-Sarraf M, Martz K, Herskovic A, Leichman L, Brindle JS, Vaitkevicius VK, et al. Progress report of combined chemoradiotherapy vs radiotherapy alone in patients with oesophegeal cancer: an intergroup study. J Clin Oncol. 1997;15:277–84.

    PubMed  CAS  Google Scholar 

  10. Khushalani NI, Leichman CG, Proulx G, Nava H, Bodnar L, Klippenstein D, et al. Oxaliplatin in combination with protracted infusion fluorouracil and radiation: report of a clinical trial for patients with oesophegeal cancer. J Clin Oncol. 2002;20:2844–50.

    Article  PubMed  CAS  Google Scholar 

  11. Magné N, Fischel JL, Formento P, Etienne MC, Dubreuil A, Marcié S, et al. Oxaliplatin, 5-fluorouracil and ionizing radiation. Importance of the sequence and influence of the p53 status. Oncology. 2003;64:280–7.

    Article  PubMed  Google Scholar 

  12. Schüller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, et al. Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients. Cancer Chemother Pharmacol. 2000;45:291–7.

    Article  PubMed  Google Scholar 

  13. Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res. 1999;5:2948–53.

    PubMed  CAS  Google Scholar 

  14. Ishikawa T, Utoh M, Sawada N, Nishida M, Fukase Y, Sekiguchi F, et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbonate in human cancer xenografts. Biochem Pharmacol. 1998;55:1091–7.

    Article  PubMed  CAS  Google Scholar 

  15. Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M, et al. Phase II study of capecitabine and oxaliplatin in first and second line treatment of advanced or metastatic colorectal cancer. J Clin Oncol. 2002;20:1759–66.

    Article  PubMed  CAS  Google Scholar 

  16. Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, et al. XELOX (Capecitabine plus oxaliplatin : active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol. 2004;22:2084–91.

    Article  PubMed  CAS  Google Scholar 

  17. World Health Organization. WHO handbook for reporting results of cancer treatment: WHO offset publication no 48. Switzerland: World Health Organization; 1979.

    Google Scholar 

  18. Cox JD, Stetz J, Aja TF. Toxicity criteria of the radiation therapy oncology group (RTOG). Int J Radiat Oncol Biol Phys. 1995;31:1341–6.

    Article  PubMed  CAS  Google Scholar 

  19. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CT CAE V. 3.0 development of comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176–81.

    Article  PubMed  Google Scholar 

  20. Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98:1521–30.

    Article  PubMed  Google Scholar 

  21. Hofstetter W, Swisher SG, Correa AM, Hess K, Putnam JB Jr, Ajani JA, et al. Treatment outcomes of resected oesophegeal cancer. Ann Surg. 2002;236:376–84. discussion. 384–385.

    Article  PubMed  Google Scholar 

  22. Keighley MRB. Gastrointestinal cancers in Europe. Aliment Pharmacol Ther. 2003;18(suppl. 3):7–30.

    Article  PubMed  Google Scholar 

  23. Wong R, Malthaner R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localised carcinoma of the oesophegus (Cochrane Review). in the Cochrane Library, Issue 1. Oxford, Update Softwer; 2003.

  24. Lorenzen S, Brücher B, Zimmermann F, Geinitz H, Riera J, Schuster T, et al. Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial. Br JCancer. 2008;99(7):1020–6.

    Article  CAS  Google Scholar 

  25. van Meerten E, Eskens FA, van Gameren EC, Doorn L, van der Gaast A. First line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophegeal cancer: a phase II study. Br J Cancer. 2007;96:1348–52.

    PubMed  Google Scholar 

  26. Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326:1593–8.

    Article  PubMed  CAS  Google Scholar 

  27. Ishikura S, Nihei K, Ohtsu A, et al. Long term toxicities after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic oesophegus. J Clin Oncol. 2002;21:2697–702.

    Article  Google Scholar 

  28. Ishida K, Ando N, Yamamoto S, Ide H, Shinoda M. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the oesophegus: a Japan Esophegeal Oncology Group (JEOG)/Japan Clinical Oncology Group Trial (JCOG9516). J pn J Clin Oncol. 2004;34:615–9.

    Article  Google Scholar 

  29. Bedenne L, Michel P, Bouché O, Milan C, Mariette C, Conroy T, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the oesophegus: FFCD 9102. J Clin Oncol. 2007;25:1160–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hend Ahmed El-Hadaad.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wahba, H.A., El-Hadaad, H.A. & Abd-Ellatif, E.A. Neoadjuvant concurrent chemoradiotherapy with capecitabine and oxaliplatin in patients with locally advanced esophegeal cancer. Med Oncol 29, 1693–1698 (2012). https://doi.org/10.1007/s12032-011-0001-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-011-0001-2

Keywords

Navigation